• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Alcon

Alcon

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

    Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

  2. Money Lessons From Baseball

    Alcon benefits from leadership positions across eye care.

  3. Healthcare on the Rebound

    The stocks mentioned in this article be holdings in the managed portfolios of Validea Capital Management, a separate asset management firm founded by Validea.com founder John Reese. Validea Capital Management, which an SEC registered investment advisory firm and a separate company from Validea.com, ...

  4. February/March 2010 Picks

    Four offerings deemed to be right for right now.

  5. Blockbusters Differentiate Novartis

    The company's diverse operating divisions and robust pipeline should lead to steady growth.

  6. Simplicity Is a Virtue for This Fund

    BBH Core Select manager Tim Hartch says focusing on easy-to-understand businesses, particularly in the financials and consumer defensive sectors, helps his team avoid negative surprises.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.